Description
Chronic liver disease (CLD) causes 1.8% of all deaths in Europe. Without policies to mitigate harmful alcohol consumption and obesity, that proportion will continue to increase. In order to address this, EASL commissioned the Hepahealth II study, a validated and peer-reviewed miscrosimulation model, to project the impact of various policy scenarios designed to improve liver health in Europe. In this episode, Professors Maria Buti, Shira Zelber-Sagi, and Peter Jepsen introduce the study, its aims, and results. Finally, Alice Chapman-Hatchett discusses more broadly the policy situation in Europe and the challenges to implementing more health focused policies.
The Hepahealth II study has been supported by an unrestricted education grant from Bristol-Myers Squibb and Gilead. Bristol-Myers Squibb and Gilead have had no input into EASL content.